How many tech companies have IPOd without product market fit? Their main problem seems to be reigning in the unrealistic growth they've been chasing. Billion d

How many tech companies have IPOd without product market fit? Their main problem seems to be reigning in the unrealistic growth they've been chasing. Billion dollar biotech companies can evaporate almost overnight, especially during a fiscal crisis. All it takes is a clinical trial gone wrong (or a competitor's gone right) and most will not be able to find enough capital to keep going. Without revenue, their survival depends entirely on the FDA and investors. It's a binary result without many options like downsizing, hunkering down, renegotiating debt, or seeking a bailout except a massive down round acquisition (or government intervention).